Holen Sie sich die Stockscreener-App
15.23
1.09%
0.11
Kalvista Pharmaceuticals Inc Aktie (KALV) Neueste Nachrichten
KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of All - pharmiweb.com
KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting - BioSpace
Travel Stocks: Should I hold or sell KalVista Pharmaceuticals Inc nowM&A Rumor & Technical Confirmation Alerts - baoquankhu1.vn
KalVista: Next Stage Of Growth For EKTERLY Lies With Pediatric Label Expansion (KALV) - Seeking Alpha
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
Market Catalysts: Does Global Blue Group Holding AG Equity Warrant have a sustainable dividendTrend Reversal & Safe Capital Preservation Plans - baoquankhu1.vn
KalVista Pharmaceuticals sees $1.5m stock purchase by Venrock - MSN
Responsive Playbooks and the KALV Inflection - Stock Traders Daily
Aug Sentiment: Is KalVista Pharmaceuticals Inc subject to activist investor interestPortfolio Value Report & Expert-Curated Trade Recommendations - baoquankhu1.vn
TD Cowen Bullish on KalVista Pharmaceuticals, Inc. (KALV) Ahead of Q4 Results - Yahoo Finance
Wall Street Analysts Believe KalVista Pharmaceuticals (KALV) Could Rally 116.4%: Here's is How to Trade - Yahoo Finance
KalVista Pharmaceuticals (KALV) Stock Analysis: Uncovering a 112% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Is KalVista Pharmaceuticals Inc forming higher highs and higher lowsJuly 2025 Recap & Safe Capital Growth Tips - baoquankhu1.vn
Quarterly Earnings: Is Intelligent Living Application Group Inc stock overvalued or fairly pricedAnalyst Downgrade & High Accuracy Swing Trade Signals - baoquankhu1.vn
What is KalVista Pharmaceuticals Incs P E ratio telling usMarket Risk Report & Technical Confirmation Alerts - baoquankhu1.vn
Bank of America Securities Reaffirms Their Buy Rating on KalVista Pharmaceuticals (KALV) - The Globe and Mail
KalVista’s Pediatric HAE Trial for Sebetralstat Reaches Completion, Setting Up a Key Catalyst for KALV - TipRanks
Does KalVista Pharmaceuticals (KALV) have the potential to rally 117.98% as Wall Street analysts expect? - MSN
Understanding the Setup: (KALV) and Scalable Risk - Stock Traders Daily
Emerald Mutual Fund Advisers Trust Grows Stake in KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
Emerald Advisers LLC Grows Position in KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
Hereditary Angioedema Market Poised for Strong Growth, Valued - openPR.com
Hereditary Angioedema Market Poised for Strong Growth, Valued at ~USD 3 Billion in 2023 and Set to Expand Through 2034: DelveInsight - Barchart.com
Multicare and KalVista collaboration in Latin America - The Pharma Letter
Multicare, KalVista to expand oral HAE treatment in Latin America - Mexico Business News
Aug Macro: What analysts say about KalVista Pharmaceuticals Inc stockQuarterly Market Review & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Recap Report: What chart patterns are forming on KalVista Pharmaceuticals IncWeekly Profit Recap & Detailed Earnings Play Strategies - baoquankhu1.vn
Can KalVista Pharmaceuticals Inc withstand a market correction2025 Sector Review & Breakout Confirmation Alerts - baoquankhu1.vn
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Published on: 2026-01-16 10:42:21 - baoquankhu1.vn
Aug Weekly: Can Zoetis Inc sustain its profitabilityOptions Play & Technical Entry and Exit Tips - baoquankhu1.vn
Does KalVista Pharmaceuticals (KALV) Have the Potential to Rally 117.98% as Wall Street Analysts Expect? - sharewise.com
Can KalVista Pharmaceuticals Inc stock sustain revenue growthQuarterly Earnings Report & Long-Term Growth Plans - Bộ Nội Vụ
KalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Down 7.2%Time to Sell? - MarketBeat
KalVista reports $49M in 2025 Ekterly revenue, shares rise - MSN
HAE treatment Ekterly hits $49M sales in months since July launch - Angioedema News
The Technical Signals Behind (KALV) That Institutions Follow - Stock Traders Daily
Analysts Expect Breakeven For KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Before Long - 富途资讯
What is HC Wainwright's Forecast for KALV FY2030 Earnings? - MarketBeat
Health Check: How Prudently Does KalVista Pharmaceuticals (NASDAQ:KALV) Use Debt? - simplywall.st
Kalvista Stock Surges On Strong EKTERLY Uptake - Nasdaq
KalVista Pharmaceuticals (NASDAQ:KALV) Hits New 52-Week High Following Analyst Upgrade - MarketBeat
KalVista Details Early Sales, Prescriber Uptake For Newly Approved Rare Swelling Drug - Benzinga
Kalvista stock surges as Stifel reiterates Buy on strong Ekterly sales By Investing.com - Investing.com South Africa
Kalvista stock surges as Stifel reiterates Buy on strong Ekterly sales - Investing.com Nigeria
Stock Market Today: Dow, Nasdaq 100 And S&P 500 Futures Gain After December Jobs Data— General Motors, Tilray In Focus (UPDATED) - Benzinga
Needham raises Kalvista Pharmaceuticals stock price target on strong Ekterly sales - Investing.com Australia
Needham raises Kalvista Pharmaceuticals stock price target on strong Ekterly sales By Investing.com - Investing.com South Africa
0.04%
1.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):